Coverage of "Capricor Therapeutics" on Cryptosearcher: the stories and the context behind them.
Capricor Therapeutics' shares dropped 70% after the FDA questioned the validity of their cell therapy trial data and changes made post-study. The upcoming advisory committee meeting could decide the therapy’s fate.
July 27, 2026
